CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 32 enrolled
Drug / intervention
Travoprost Ophthalmic Solution 0.004%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01995136
NCT01995136Phase 4Completed
CompareCT.gov

Investigation of the Effect of Travoprost Ophthalmic Solution of Lowering Intraocular Pressure in Patients With Normal Tension Glaucoma

Alcon Research·interventional·Posted Nov 26, 2013·Updated Oct 7, 2015

In Brief

A Phase 4 clinical trial evaluating Travoprost Ophthalmic Solution 0.004% for Normal Tension Glaucoma and Ocular Hypertension. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate IOP reduction efficacy of travoprost 0.004% ophthalmic solution (TRAVATAN Z®) in subjects with normal tension glaucoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNormal Tension Glaucoma, Ocular Hypertension
CountriesJapan
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 26, 2013
Enrollment StartSep 1, 2013
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.6 years ago

Interventions

Travoprost Ophthalmic Solution 0.004%drug

benzalkonium chloride (BAC) free